Key Takeaways
- •An evidence tier belongs to a formulation and an indication, never to a molecule. Thymosin beta-4 as an eye drop for corneal healing and TB-500 as a research reagent are the same peptide and completely different evidence positions.
- •A registered trial whose results were never published is weaker evidence than no trial at all. Publication bias runs one direction: results that support a compound get written up.
- •BPC-157 is the clearest example. As PL 14736 it completed a Phase 2 study in ulcerative colitis. The full results have never appeared in a peer-reviewed journal.
- •"Approved cousin" is the most common substitution error in this market. Afamelanotide holds a US approval; melanotan II does not, and they are different molecules with different receptor selectivity.
- •Withdrawal is not the same as failure. Sermorelin's approval was pulled in 2008 over manufacturing and supply, not over safety or efficacy, and the distinction changes how you read the compound.
- •Retatrutide has a complete Phase 3 package and no approval anywhere. Those two facts are both true right now, and a guide that states only one of them is selling you something.
Thymosin beta-4 has been through a Phase 3 clinical trial. That sentence is true, and nearly every use of it you will meet online is misleading.
The trial was RGN-259: a preservative-free eye drop, in neurotrophic keratopathy, a rare corneal disease. Recruitment was slow, the study was closed early, and the analysis ran on 18 patients. Complete corneal healing at four weeks occurred in 6 of 10 treated subjects against 1 of 8 on placebo, which is a real signal, but the primary endpoint came in at p = 0.0656 and therefore missed. A later European Phase 3, SEER-3, missed its primary endpoint as well.
So the honest version of the sentence is: a topical ocular formulation of thymosin beta-4 has twice failed to clear a Phase 3 primary endpoint in an eye disease. That is a completely different claim from the one people take away, and it says nothing whatsoever about a lyophilised vial of TB-500 sitting on a bench.
This article is a map of where each commonly discussed peptide actually sits in the evidence, and a method you can apply yourself to any compound not on the list. We sell most of the compounds in the table below, including TB-500 and BPC-157. Several of them land in the two weakest tiers, and the table says so rather than routing around it. Everything Volta sells is supplied for laboratory research use only.
The five tiers
The ladder below is ordered by one question only: how much of this compound's story has been checked by somebody with no stake in the answer?
| Tier | What it means | The test that places a compound here |
|---|---|---|
| A | An approved medicine somewhere | A regulator has reviewed a full manufacturing, safety and efficacy dossier and issued a marketing authorisation |
| B | Phase 3 complete, no regulatory decision yet | Adequately powered confirmatory trials have reported; no agency has ruled |
| C | Published controlled human trials, no approval for the studied use | Peer-reviewed human data exists for a named formulation and indication |
| D | Human trials run, results never published | The study exists in a registry. The evidence does not exist in the literature |
| E | Preclinical only | Animal or cell data, and nothing else |
Two rules govern the ladder, and both are routinely broken by vendor content.
The tier attaches to the formulation and the indication. Not to the sequence. An eye drop is not a vial. An oral tablet is not a parenteral preparation. A trial in one disease is not evidence in another. Every time you see a peptide described as "clinically studied" with no formulation and no indication attached, the two facts that would let you judge the claim have been removed.
The tier is the highest rung with real evidence under it, and everything below still applies. A Tier A compound still has an impurity profile, a counterion, a storage curve and a shelf life. Approval upstream tells you nothing about the vial in front of you.
Why Tier D is worse than Tier E
This is the counterintuitive one, and it is the most useful idea here.
A Tier E compound has animal data and no human data. That is an honest gap: nobody has looked yet.
A Tier D compound has a registered human trial that finished and never reported. That is not a gap, it is a missing result, and missing results are not missing at random. A trial that produces a clean positive gets written up, presented and press-released, because publication is how a sponsor converts a result into value. A trial that produces a null or an ambiguous result frequently goes quiet.
So the absence of a publication behind a completed trial is weak evidence of a disappointing trial. Not proof, evidence. When you find a compound whose strongest human claim points at a registry entry with no linked publication, treat the tier as a warning rather than a credential.
The two clearest cases in this market:
| Compound | Trial | What happened |
|---|---|---|
| BPC-157 (as PL 14736) | Multicentre randomised double-blind placebo-controlled Phase 2, enema formulation, mild-to-moderate ulcerative colitis | Completed. No full results in any peer-reviewed journal |
| Ipamorelin | Phase 2 programme in postoperative ileus (Helsinn) | Discontinued for lack of efficacy. In 117 bowel-resection patients it beat placebo on neither the primary nor any secondary endpoint. A 320-patient study, NCT01280344, completed in 2014 and posted no results |
Both compounds are widely sold. Both are frequently described as "studied in humans," which is true and, presented without the outcome, actively misleading.
The map
Highest tier reached, with the specific evidence that puts it there. Where a compound's best evidence is for a different formulation than the one sold as a research reagent, the table says so, because that is the whole point.
| Compound | Tier | The evidence that places it | What that evidence does not cover |
|---|---|---|---|
| Semaglutide | A | Approved medicine in Canada, the US and elsewhere; large confirmatory trial programme | Nothing about a research-grade vial's identity, content or handling |
| Tirzepatide | A | Approved medicine, dual GIP/GLP-1 receptor agonist | As above |
| Tesamorelin | A | Approval issued 10 November 2010 for HIV-associated lipodystrophy, on two randomised placebo-controlled Phase 3 studies totalling 816 patients | One indication, one population, one formulation |
| HCG | A | Long-established approved product with a defined clinical role | Research-grade material is not the approved product |
| Retatrutide | B | Five positive Phase 3 trials reported in the TRIUMPH programme; regulatory submission signalled for Q1 2027 | No agency has completed a review. Not approved anywhere |
| CJC-1295 (with DAC) | C | Teichman et al., J Clin Endocrinol Metab 2006: two randomised, placebo-controlled, ascending-dose trials in healthy adults aged 21 to 61. Plasma GH rose 2- to 10-fold for six days or more, IGF-I 1.5- to 3-fold for 9 to 11 days | Pharmacology, not outcomes. No approval. The no-DAC variant is a different molecule with different kinetics |
| Thymosin beta-4 / TB-500 | C | Phase 3 work exists, as RGN-259 ophthalmic solution in corneal disease. SEER-1 missed on p = 0.0656 with 18 patients after early closure; SEER-3 missed its primary endpoint | Topical ocular delivery to the cornea. Not a systemic preparation, not any other tissue |
| GHK-Cu | C | Small human studies exist, predominantly topical and cosmetic, alongside a substantial cell-biology literature | Small, short, cosmetic endpoints. Not a systemic evidence base |
| BPC-157 | D | Phase 2 in ulcerative colitis as PL 14736, completed, results never published in the peer-reviewed literature | Everything. The most-cited human study is one you cannot read |
| Ipamorelin | D | Phase 2 in postoperative ileus, discontinued for lack of efficacy; a 320-patient study posted no results | The published record is a negative one |
| Sermorelin | A, lapsed | Held an approval as Geref for paediatric growth hormone deficiency; voluntarily withdrawn in 2008 over manufacturing and supply, not safety or efficacy | Currently approved nowhere. The withdrawal reason matters and is usually omitted |
| Melanotan II | E | No approval, no completed confirmatory programme. The related but distinct MC1R-selective analogue afamelanotide received a US approval on 8 October 2019 for erythropoietic protoporphyria | Afamelanotide's approval is not melanotan II's evidence. Different molecule, different selectivity |
| MOTS-c | E | Mitochondrial-derived peptide with an active cell and animal literature and human genetic association work | No controlled interventional human trial of the peptide as supplied |
| KPV | E | Tripeptide fragment with preclinical anti-inflammatory data | No human trial programme |
In Stock and Shipping from British Columbia
Every vial below ships domestically within Canada with a batch-specific Certificate of Analysis. Supplied for laboratory research use only.
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
KLOW 80mg
80mg
KPV 10mg
10mg
Ipamorelin 5mg
5mg
MOTS-C 10mg
10mg
TB-500 10mg
10mg
GHK-Cu 100mg
100mg
SS-31 10mg
10mg
5-Amino-1MQ 10mg
10mg
>99% HPLC purity standard. Read the Certificates of Analysis.
See the full Canadian catalogueThe approved-cousin problem
The single most common way a reader is misled is not a false statement. It is a true statement about a neighbouring molecule.
Melanotan II and afamelanotide are the textbook case. Afamelanotide is an approved medicine with a defined indication, a manufacturer, a dossier and a post-marketing record. Melanotan II is none of those things. They are related, they act on melanocortin receptors, and they are not the same compound: afamelanotide is MC1R-selective, which is precisely why its effects and its risk profile are characterised the way they are. A page that discusses melanotan II and then cites afamelanotide's approval has swapped the subject mid-argument.
The same manoeuvre appears with sermorelin and tesamorelin, both GHRH analogues. Tesamorelin holds a current approval. Sermorelin's lapsed in 2008. Writing about "GHRH analogues" and citing the tesamorelin dossier lets a reader carry an approval across to a compound that does not have one.
The check is mechanical: for every citation, confirm that the molecule named in the source is the molecule named in the sentence. Not the class, not the mechanism, not the receptor family. The molecule.
How to place a compound yourself
Four steps, about fifteen minutes, and it works for anything not on the list above.
1. Find the highest-tier human claim, then find its source. Not a summary of the source. Vendor pages, and a good deal of press coverage, cite each other in circles. Follow it back until you reach either a journal article or a trial registry entry.
2. Read the formulation and the indication off the source, and write both down. This is the step that catches most errors. "Phase 3" means nothing until you know Phase 3 of what, delivered how, in whom.
3. If the source is a registry entry, check whether results were ever posted or published. A completed trial with no linked results is Tier D. Note the completion date: the further in the past, the more meaningful the silence.
4. Check the endpoint, not the narrative. A trial that missed its primary endpoint but reported an encouraging secondary is a missed trial. Secondary endpoints generate hypotheses; they do not establish effects.
The evidence grade tool walks this scoring in the browser, and the regulatory status checker covers where a compound currently stands with regulators. For reading the underlying literature critically, the research literacy guide covers trial design, and the myths guide covers the claims that recur most often.
What the tier does and does not change about a purchase
Not as much as you might expect, and this is worth being blunt about, because it cuts against a supplier's interest.
A high tier is a statement about a molecule's biology, established with material that a sponsor manufactured to pharmaceutical standards, characterised exhaustively, and released against a specification. None of that transfers to a vial you buy. Semaglutide is Tier A, and a research-grade semaglutide vial from any supplier is still an unverified object until its own documentation says otherwise.
So the tier answers "is there a reason to study this at all?" and the certificate answers "is this the thing, and how much of it is there?" They are independent questions, and a strong answer to one is routinely used to imply an answer to the other.
That is the substitution to watch for on any storefront, ours included: an approval or a trial result placed next to a product, so the credibility of the molecule's literature transfers to the vial. The literature belongs to the compound. The vial has to earn its own.
For the second question, the companion piece is how to tell if a peptide supplier is legitimate, which covers certificate traceability and the difference between purity and content. The quality page sets out Volta's own standard and the COA explainer walks a certificate field by field.
Frequently Asked Questions
Does a Phase 3 trial mean a peptide works?
No. It means a confirmatory trial was run. The result can be positive, negative or ambiguous, and a trial that missed its primary endpoint is still "a Phase 3 trial" in a sentence that omits the outcome. Thymosin beta-4 has two Phase 3 misses in corneal disease and is regularly described in vendor copy as having Phase 3 evidence, which is technically accurate and gives the reader precisely the wrong impression.
Why is BPC-157 rated so low when so much is written about it?
Because volume of writing and weight of evidence are unrelated. BPC-157 has a large and genuinely interesting animal literature, much of it from a single research group, and one completed Phase 2 human study whose full results have never been published in a peer-reviewed journal. The strongest human claim about the compound rests on a document that is not in the literature.
Is a compound with no human data automatically a bad choice for research?
Not at all, and treating it that way would rule out most of what laboratory research exists to do. A preclinical-only compound is a legitimate research subject. The problem is never the tier itself, it is a tier being quietly overstated: Tier E material described in language borrowed from Tier A.
If a peptide is an approved medicine, is research-grade material equivalent?
No. An approval covers a specific product made by a specific manufacturer to a registered process and released against a specification, with identity, content, impurities, sterility and stability all controlled. Research-grade material shares the sequence and none of that apparatus. This is why a certificate tied to the actual lot matters regardless of how well studied the molecule is.
How often does this map need rechecking?
At least annually, and before relying on any single entry. Retatrutide is the live example: it moved from Phase 2 to a complete Phase 3 package inside about two years, and a regulatory decision would move it again. Tiers move up when trials report and down when nothing does.
Where does the "research use only" label fit into this?
It is a statement about how material is supplied and what it has been assessed for, not a grade of evidence. A Tier A molecule sold as a research reagent is still research-grade material: unassessed by any regulator in that form, and not authorised for any use in people. The tier and the label answer different questions, and neither substitutes for the other.
